Acute demyelinating optic neuritis: A review

Steven David Brass, Robert Zivadinov, Rohit Bakshi

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

Acute demyelinating optic neuritis (ON) is a leading consideration in the differential diagnosis for young adults presenting with sudden onset of painful unilateral visual loss. Multiple sclerosis (MS) is believed to be the most common etiology for ON. Nearly 50% of MS patients will develop ON, and in 15-20% of cases, ON will be the initial manifestation of the illness. Conventional and emerging magnetic resonance imaging (MRI) techniques have provided greater insight into the pathophysiology of ON, and conventional MRI has also allowed clinicians to better estimate the future risk of MS. At 10 years after ON, patients with zero, one, or two or more brain lesions on T2-weighted MRI sequences demonstrated a 22%, 52%, and 56% risk of developing MS, respectively. Treatment with high dose intravenous methylprednisolone may accelerate visual recovery in patients with acute ON, but has little impact on long term visual outcome. Disease modifying therapies in patients with acute demyelinating ON should be considered as a treatment option at the time of initial presentation in those patients whose initial brain MRI shows demyelinating lesions as these therapies have been shown in to be effective at reducing the future risk of MS.

Original languageEnglish (US)
Pages (from-to)2376-2390
Number of pages15
JournalFrontiers in Bioscience
Volume13
Issue number6
DOIs
StatePublished - 2008
Externally publishedYes

Fingerprint

Optic Neuritis
Optics
Multiple Sclerosis
Magnetic resonance
Magnetic Resonance Imaging
Imaging techniques
Brain
Methylprednisolone
Therapeutics
Young Adult
Differential Diagnosis
Recovery

Keywords

  • Clinically isolated syndrome
  • Multiple sclerosis
  • Optic neuritis
  • Review
  • Treatment trial

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)
  • Biochemistry
  • Cell Biology
  • Medicine(all)

Cite this

Brass, S. D., Zivadinov, R., & Bakshi, R. (2008). Acute demyelinating optic neuritis: A review. Frontiers in Bioscience, 13(6), 2376-2390. https://doi.org/10.2741/2851

Acute demyelinating optic neuritis : A review. / Brass, Steven David; Zivadinov, Robert; Bakshi, Rohit.

In: Frontiers in Bioscience, Vol. 13, No. 6, 2008, p. 2376-2390.

Research output: Contribution to journalArticle

Brass, SD, Zivadinov, R & Bakshi, R 2008, 'Acute demyelinating optic neuritis: A review', Frontiers in Bioscience, vol. 13, no. 6, pp. 2376-2390. https://doi.org/10.2741/2851
Brass, Steven David ; Zivadinov, Robert ; Bakshi, Rohit. / Acute demyelinating optic neuritis : A review. In: Frontiers in Bioscience. 2008 ; Vol. 13, No. 6. pp. 2376-2390.
@article{126039eb79a04eac90c57e9557e5e560,
title = "Acute demyelinating optic neuritis: A review",
abstract = "Acute demyelinating optic neuritis (ON) is a leading consideration in the differential diagnosis for young adults presenting with sudden onset of painful unilateral visual loss. Multiple sclerosis (MS) is believed to be the most common etiology for ON. Nearly 50{\%} of MS patients will develop ON, and in 15-20{\%} of cases, ON will be the initial manifestation of the illness. Conventional and emerging magnetic resonance imaging (MRI) techniques have provided greater insight into the pathophysiology of ON, and conventional MRI has also allowed clinicians to better estimate the future risk of MS. At 10 years after ON, patients with zero, one, or two or more brain lesions on T2-weighted MRI sequences demonstrated a 22{\%}, 52{\%}, and 56{\%} risk of developing MS, respectively. Treatment with high dose intravenous methylprednisolone may accelerate visual recovery in patients with acute ON, but has little impact on long term visual outcome. Disease modifying therapies in patients with acute demyelinating ON should be considered as a treatment option at the time of initial presentation in those patients whose initial brain MRI shows demyelinating lesions as these therapies have been shown in to be effective at reducing the future risk of MS.",
keywords = "Clinically isolated syndrome, Multiple sclerosis, Optic neuritis, Review, Treatment trial",
author = "Brass, {Steven David} and Robert Zivadinov and Rohit Bakshi",
year = "2008",
doi = "10.2741/2851",
language = "English (US)",
volume = "13",
pages = "2376--2390",
journal = "Frontiers in Bioscience - Landmark",
issn = "1093-9946",
publisher = "Frontiers in Bioscience",
number = "6",

}

TY - JOUR

T1 - Acute demyelinating optic neuritis

T2 - A review

AU - Brass, Steven David

AU - Zivadinov, Robert

AU - Bakshi, Rohit

PY - 2008

Y1 - 2008

N2 - Acute demyelinating optic neuritis (ON) is a leading consideration in the differential diagnosis for young adults presenting with sudden onset of painful unilateral visual loss. Multiple sclerosis (MS) is believed to be the most common etiology for ON. Nearly 50% of MS patients will develop ON, and in 15-20% of cases, ON will be the initial manifestation of the illness. Conventional and emerging magnetic resonance imaging (MRI) techniques have provided greater insight into the pathophysiology of ON, and conventional MRI has also allowed clinicians to better estimate the future risk of MS. At 10 years after ON, patients with zero, one, or two or more brain lesions on T2-weighted MRI sequences demonstrated a 22%, 52%, and 56% risk of developing MS, respectively. Treatment with high dose intravenous methylprednisolone may accelerate visual recovery in patients with acute ON, but has little impact on long term visual outcome. Disease modifying therapies in patients with acute demyelinating ON should be considered as a treatment option at the time of initial presentation in those patients whose initial brain MRI shows demyelinating lesions as these therapies have been shown in to be effective at reducing the future risk of MS.

AB - Acute demyelinating optic neuritis (ON) is a leading consideration in the differential diagnosis for young adults presenting with sudden onset of painful unilateral visual loss. Multiple sclerosis (MS) is believed to be the most common etiology for ON. Nearly 50% of MS patients will develop ON, and in 15-20% of cases, ON will be the initial manifestation of the illness. Conventional and emerging magnetic resonance imaging (MRI) techniques have provided greater insight into the pathophysiology of ON, and conventional MRI has also allowed clinicians to better estimate the future risk of MS. At 10 years after ON, patients with zero, one, or two or more brain lesions on T2-weighted MRI sequences demonstrated a 22%, 52%, and 56% risk of developing MS, respectively. Treatment with high dose intravenous methylprednisolone may accelerate visual recovery in patients with acute ON, but has little impact on long term visual outcome. Disease modifying therapies in patients with acute demyelinating ON should be considered as a treatment option at the time of initial presentation in those patients whose initial brain MRI shows demyelinating lesions as these therapies have been shown in to be effective at reducing the future risk of MS.

KW - Clinically isolated syndrome

KW - Multiple sclerosis

KW - Optic neuritis

KW - Review

KW - Treatment trial

UR - http://www.scopus.com/inward/record.url?scp=38449103422&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=38449103422&partnerID=8YFLogxK

U2 - 10.2741/2851

DO - 10.2741/2851

M3 - Article

C2 - 17981719

AN - SCOPUS:38449103422

VL - 13

SP - 2376

EP - 2390

JO - Frontiers in Bioscience - Landmark

JF - Frontiers in Bioscience - Landmark

SN - 1093-9946

IS - 6

ER -